Summit Therapeutics Inc. reported a net loss of $215,700 for the three months and $405,124 for the six months ended June 30, 2026, compared with losses of $565,708 and $628,621 a year earlier. Operating expenses were $220,496 for the quarter, driven by research and development of $157,733 and general and administrative costs of $62,763. Stock-based compensation remained significant at $68,706 for the quarter, though lower than the prior-year period.
Cash used in operating activities reached $263,415 in the first half of 2026. As of June 30, 2026, cash and cash equivalents were $419,365 and short-term investments were $271,313, against an accumulated deficit of $2,699,283. Management states that this liquidity is not sufficient to fund planned operations for at least one year and that these conditions raise substantial doubt about the company’s ability to continue as a going concern, making additional financing critical.
The company’s strategy centers on ivonescimab, a bispecific PD-1/VEGF-A antibody being developed across multiple Phase III trials in non-small cell lung and colorectal cancers. In EGFR‑mutated NSCLC after EGFR-TKI therapy, the HARMONi trial showed a progression free survival hazard ratio of 0.52, while overall survival trended favorably but did not reach statistical significance. A Biologics License Application for this setting has been accepted by the FDA with a Prescription Drug User Fee Act goal action date of November 14, 2026; the FDA has cautioned that a statistically significant overall survival benefit is expected for approval.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.